Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization
27 Giugno 2022 - 12:50PM
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”)
(Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on
developing novel drugs for the targeted treatment of
neuropsychiatric disorders, epilepsy, and pain, today announced
that Dr. Alan Kozikowski will no longer serve in the role of Chief
Scientific Officer.
“Alan has been with Bright Minds since the beginning, and his
leadership was instrumental in shaping our vision and discovery
efforts. As Bright Minds advances its first drug candidate BMB-101,
we are now transitioning from a discovery to a clinical phase
company and look forward to this new stage of growth. On behalf of
the entire Company, I would like to thank Alan for his service and
dedication,” said Ian McDonald, CEO and Co-founder of Bright Minds
Biosciences.
Bright Minds has initiated a search for its new Chief Scientific
Officer, and Jan Torleif Pedersen, PhD, MSc, a current member of
the Board of Directors, will serve as the interim Chief Scientific
Officer until the position is filled.
Dr. Pedersen is an innovative and highly experienced leader in
drug discovery research, with more than 25 years of expertise in
neuroscience research management. Dr. Pedersen spent 20 years at
Lundbeck, a global pharmaceutical company specializing in brain
diseases, in positions of increasing responsibility, including
building its neurodegeneration/Alzheimer’s disease pipeline and
bringing research programs to the clinic. Dr. Pedersen is a
co-founder of three biotech companies, among these, Acadia
Pharmaceuticals.
About BMB-101
BMB-101, a 5-HT2C selective and biased agonist, has demonstrated
compelling activity in a host of in-vitro and in-vivo non-clinical
tests. Compared to Locaserin, BMB-101 exhibits strong Gq signaling
coupled with minimal beta arrestin recruitment. Mechanistically,
Serotonin (5- Hydroxytryptamine, 5-HT) is a monoamine
neurotransmitter widely expressed in the central nervous system,
and drugs modulating 5-HT have made a major impact in mental health
disorders. Central 5-HT systems have long been associated with the
control of ingestive behavior and the modulation of behavioral
effects of psychostimulants, opioids, alcohol and nicotine. Over
the past decade, the various 5-HT receptor subtypes have been
cloned and characterized. Results of clinical trials and animal
studies indicate that 5-HT2C up receptor agonists may have
therapeutic potential in the treatment of addiction by decreasing
the intake of opioids as well as impulsive behavior that can
escalate compulsive drug use.
About Bright Minds
Bright Minds is focused on developing novel transformative
treatments for neuropsychiatric disorders, epilepsy, and pain.
Bright Minds has a portfolio of next-generation serotonin agonists
designed to target neurocircuit abnormalities that are responsible
for difficult to treat disorders such as resistant epilepsy,
treatment resistant depression, PTSD, and pain. The Company
leverages its world-class scientific and drug development expertise
to bring forward the next generation of safe and efficacious drugs.
Bright Minds’ drugs have been designed to potentially retain the
powerful therapeutic aspects of psychedelic and other serotonergic
compounds, while minimizing the side effects, thereby creating
superior drugs to first-generation compounds, such as
psilocybin.
Forward-Looking Information and Additional Cautionary
Language
This news release contains statements and information that, to
the extent that they are not historical fact, may constitute
“forward-looking information” within the meaning of applicable
securities legislation. Forward-looking information may include
financial and other projections, as well as statements regarding
future plans, objectives or economic performance, or the assumption
underlying any of the foregoing. Forward looking information in
this news release contains information related to the commencement
of drug trials with respect to the Company’s BMB-101 candidate, the
Company’s search for a new Chief Scientific Officer and Dr.
Pederson’s role as interim Chief Scientific Officer continuing
until such search is complete. This news release uses words such as
“may,” “would,” “could,” “likely,” “expect,” “anticipate,”
“believe,” “intend,” “plan,” “forecast,” “project,” “estimate,”
“outlook,” and other similar expressions to identify
forward-looking information.
Forward-looking information involves significant risks,
assumptions, uncertainties and other factors that may cause actual
future results or anticipated events to differ materially from
those expressed or implied in any forward-looking statements and
accordingly, should not be read as guarantees of future performance
or results. Assumptions used to develop the forward-looking
information in this news release includes commencement of drug
trials with respect to the Company’s BMB-101 candidate,
availability of suitable candidates for the role of Chief
Scientific Officer and Dr. Pederson’s continued willingness to
fulfill the role on an interim basis.
Actual results, performance or achievement could differ
materially from that expressed in, or implied by, any
forward-looking information in this news release and, accordingly,
readers should not place undue reliance on any such forward-looking
information. Further, any forward-looking statement speaks only as
of the date on which such statement is made. New factors emerge
from time to time, and it is not possible for management to predict
all of such factors and to assess in advance the impact of each
such factor on the Company’s business or the extent to which any
factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. The Company does not undertake any obligations to
update any forward-looking information to reflect information,
events, results, circumstances or otherwise after the date hereof
or to reflect the occurrence of unanticipated events, except as
required by law.
Investor Contacts:Lisa WilsonE:
lwilson@insitecony.comT: 917-543-9932
Grafico Azioni Bright Minds Biosciences (NASDAQ:DRUG)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Bright Minds Biosciences (NASDAQ:DRUG)
Storico
Da Giu 2023 a Giu 2024